The FDA accepts OUS (Outside US) data. EU Notified Bodies accept US IDE and registry data. Eclevar MedTech's US Corridor maximises the regulatory value of every clinical data point you generate.
The FDA explicitly accepts OUS (Outside US) clinical data, including EU ISO 14155 trials. In return, EU Notified Bodies accept US IDE (Investigational Device Exemption) data. Designing one unified clinical strategy from Day 1 prevents the multi-million dollar mistake of running redundant clinical trials.
A manufacturer with US IDE clinical trial data or robust US registry data possesses prospective evidence that directly addresses EU MDR Annex XIV requirements. Conversely, an EU manufacturer with a strong PMCF study has the OUS data needed to support a 510(k). The key is structuring the data correctly to satisfy both simultaneously.
The US is the largest medical device market, making it a mandatory milestone for European MedTechs planning expansion.
FDA explicitly recognizes ISO 14155:2020 for the acceptance of foreign clinical data in 510(k) and PMA submissions.
Average timeline reduction when dual FDA/CE Mark clinical pathways are co-designed and executed.
US manufacturers with FDA-approved clinical data can significantly reduce or eliminate the need for a new European clinical investigation by leveraging this evidence in a structured CER architecture.
Clinical trials conducted under an FDA IDE contain prospective outcome data that directly satisfies EU MDR Annex XIV Part B requirements.
US national registries (like ACC/NCDR or VQI) provide massive datasets. We format this into compliant EU PMCF Evaluation Reports.
We extract and reformat safety data from the FDA MAUDE database, adapting it to MEDDEV 2.7/1 rev.4 evidence-grading criteria.
European manufacturers can leverage their CE Mark clinical investigation data, EU PMCF study outputs, and CER evidence package as valid OUS data to support FDA submissions.
The FDA officially recognizes ISO 14155:2020. EU clinical data collected under this standard is routinely accepted to support 510(k) or PMA submissions.
Where the FDA requires post-market surveillance (like Section 522 orders), data generated from robust EU PMCF programs can satisfy FDA reporting.
Before submitting EU data to the FDA, we construct a powerful Q-Submission briefing package to negotiate and mitigate refusal risks.
The biggest pitfall for US manufacturers entering Europe is assuming that an FDA 510(k) clearance based on "Substantial Equivalence" (using a predicate device) is enough for a CE Mark. Under EU MDR, equivalence rules are exceptionally strict. Eclevar specializes in translating 510(k) cleared products into EU MDR compliance by structuring PMCF studies and existing literature to build the direct clinical evidence that Notified Bodies demand.
Catalogue available US clinical data: IDE trial results, MAUDE data, and US national registry contributions.
US evidence is mapped against EU MDR Annex XIV. Strict check on EU equivalence rules for 510(k) devices.
Full CER authored using US data as primary evidence. ISO 14155 bridging arguments applied where necessary.
CER submitted to an EU Notified Body. Eclevar manages all interactions defending the acceptability of US data.
Assessment of EU clinical investigation data (ISO 14155) and PMCF outputs for FDA OUS acceptability.
Drafting a strategic Pre-Submission briefing package to negotiate the use of EU data with FDA reviewers.
Official meeting with FDA to confirm data acceptability and define if a small US bridging study is needed.
Final preparation of the regulatory submission using the pre-agreed European dataset. Formal FDA filing.
A US cardiovascular manufacturer running a massive IDE trial aimed for CE Mark. Instead of running a parallel European study, Eclevar architected their CER around the FDA data, validating population equivalence. The Notified Body accepted the IDE data in full, saving millions in clinical costs.
A European orthopaedic company wanted US market access but lacked a clear predicate device for a standard 510(k). Eclevar managed a Q-Submission showing the FDA that the company's 3-year EU PMCF registry data met OUS standards. The FDA accepted the data to support a successful clearance.
"We thought we had to start a completely new clinical trial in Germany for our CE Mark. Eclevar mapped our US IDE data to Annex XIV and defended it flawlessly during the Notified Body audit. They saved us two years and millions of dollars."
"The FDA Q-Submission process is daunting. Eclevar structured our European PMCF data so perfectly that the FDA agreed to accept it as our primary clinical evidence for clearance. Incredible strategic insight."
Yes. The FDA accepts "Outside US" (OUS) data, particularly when it complies with ISO 14155:2020. We use the Pre-Submission (Q-Sub) process to get formal agreement from the FDA before filing.
No. This is a common misconception. The FDA 510(k) relies heavily on "Substantial Equivalence," which EU MDR heavily restricts. We must restructure your data and often implement a PMCF strategy to meet European requirements.
Absolutely. MILO EDC is fully compliant with 21 CFR Part 11 (FDA) and GDPR (EU), allowing you to run a single global study that outputs compliant datasets for both regulatory bodies.
Book a US Corridor consultation. We assess your existing clinical evidence and map the fastest compliant pathway to navigate FDA and EU MDR requirements simultaneously.
Book a Free Corridor Consultation
